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ABSTRACT: Three years constant study was performed in order to 
screen the drug resistant Candida presence in the sputum of TB 
clinic attendees in and around Chidambaram, Tamilnadu, India. 
Totally 3100 sputum specimens were screened by using the routine 
mycological procedures. We could able to obtain 20.5% of Candida 
strains from 3100 TB clinic attendees and Candida albicans, Candida 
tropicalis, Candida dubliniensis and Candida krusei was identified. 
Overall based on our study report we could able to report 48%, 
25% and 22% antifungal resistance by Candida strains towards the 
antifungal drugs Nystatin, Azole drugs and Amphotericin B. From 
this we can conclude and suggest that the occurrence of drug 
resistant Candida strains in the sputum/ respiratory tract of the 
patients with respiratory tract infections is not uncommon. Therefore 
the periodical survey of the drug resistant Candida strains is 
essential not only to for the development of new antifungal drugs 
and in the appropriate antifungal drug selection for the earliest 
treatment for the patient care, but also equally important for the 
prevention of these drug resistant Candida transmitted from the 
patients to the public. 
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Introduction 
Candida species are yeast like fungi that can form pseudohyphae. 
For most of the part Candida species are confined to human and 
animal reservoirs; however they are frequently recovered from the 
hospital environment, including on the foods, counter tops, air 
conditioning vents, floors, respirators. They are also normal 
commensals of skin and mucosal membranes of the GIT, genito 
urinary and respiratory tracts.1,2,3 
Candidiasis is one of the most frequent opportunistic infection found 
in human beings and animals. Commonly it is seen in 
immunocompromised as well as immunocompetant hosts. The 
incidence rate of fungal infections rose significantly on past two 
decades4. While Candida albicans is considered as primary agent of 
these diseases. Other species like Candida dubliniensis, Candida 
tropicalis, Candida krusei etc has also been shown to produce severe 
systemic infection5. 
The respiratory tract Candidiasis is mainly seen as 1) Laryngeal 
Candidiasis 2) Candida tracheo bronchitis and 3) Candida 
pneumonia. Candida laryngitis may occur in the absence of 
oropharyngeal or esophageal Candidiasis, presenting as hoarseness 
in a patient receiving antibiotics. Sore throat and dysphagia are 
more readily attributable to accompanying pharyngitis or 
oesophagitis. On Endoscopy shallow ulcerations or grey members 
are seen on an erythematous larynx. Pulmonary Candidiasis is more 
of an autopsy than a clinical entity. Pulmonary lesions araise from 
hematogenous seeding, causing diffuse recticulonodular streaking 
which is difficult to see on chest X ray unless another pulmonary 
disorder is also present, such as adult respiratory distress syndrome 
or congestive heart failure.5 
During the first two decades of this century, many researches have 
been made extensive studies on mycoses caused by yeasts.  Tea 
tasters cough has been considered to be an early account of 
broncho pulmonary Candidiasis. They suggested that yeast species 
other than monilia albicans might be involved in Candidiasis and 
made the first descriptions of the species currently known as 
Candida guillermondii, Candida krusei, Candida kefyr, and Candida 
tropicalis.  
In India, it seems to be limited data available on antifungal 
susceptibility of Candida species especially isolated from the sputum. 
The present study aim to focus on the isolation  of different Candida 
species present in the sputum of the TB clinic attendees in order to 
perform the in vitro antifungal susceptibility pattern of these isolates 
and to screen the drug resistant Candida strains if any associated 
with these TB clinic attendees of various clinics in and around 
Chidambaram.  
Even though Candida has been considered as one of the organisms 
source from endogenous site eg: skin, oral cavity, genito urinary 
tract, gastro intestinal tract, few studies has been performed. The 
study related to the isolation and identification of the drug resistant 
Candida strains from the human sputum is seems to be rare and 
proved their presence outside, yet the study related to the sources 
of infection concern to Candida, it has not proven or justify the 
human as the sources of Candida infection especially the spread 
among the human respiratory tract to human respiratory tract. 
And it is well known fact the transmission of the pathogen from the 
human respiratory tract through the droplet nuclei or by aerosols 
and the spread of respiratory tract infection are coming fast when 
the already affected individuals serves as the source of infection 
either as patients or carriers. 
There are sufficient scientific publications available for the reference 
of respiratory tract infection and the association of Candida but 
there are very few or occasional publications are available regarding 
the carriage rate of Candida in the respiratory tract of the TB clinic 
attendees. To best of our knowledge, there is no evidenced 
publication available pertaining to the antifungal susceptibility 
pattern of the Candida species isolated from the sputum of the TB 
clinic attendees and the evaluation of the drug resistance among 
them.  
Since Candida involves in opportunistic infection with debilitated 
persons and also causes secondary infection even among immuno 
competent persons and also developing drug resistance, it is 
necessary to give importance to the evaluation of the drug resistant 
Candida strains present in the respiratory tract of the patients 
suffering from the respiratory tract infections. 
In our present study, in order  to evaluate the occurrence of drug 
resistant Candida present  in the respiratory tract of the individuals 
suffering from the respiratory tract infection, we selectively  chosen 
the TB clinic attendees since these cases contains both TB + ve and 
TB – ve individuals with clinically proven respiratory tract infections. 
 
Materials and methods 
Subjects included and source 
Patients with signs and symptoms of chronic respiratory tract 
infection attended the out patient TB clinics at Rajah Muthiah 
medical College and Hospital, Chidambaram, Tamil Nadu, India, 
Mahatma Gandhi Medical College & Research Institute, Puducherry 
and also various private nursing homes in and around 
Chidambaram, India were included in this study. A total of 3100 
patient’s samples collected during January 2007 to December 2009.  
 
Selection criteria  
The fresh untreated cases with signs and symptoms of respiratory 
tract infection attended the TB clinics were included in this study. 
Prior to specimen collection, patients were enquired about the 
antibiotic treatment if they were undergoing or underwent and it 
was recorded. 
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Specimens Collection 
Three consecutive days early morning saliva and sputum was 
collected from 3100 TB clinic attendees in separate sterile 
container.3 days early morning saliva were collected in a sterile 
container after gargling mouth with sterile normal saline. Patients 
were instructed to collect sputum samples after the deep cough in 
order to correlate Candida infection. 
 
Direct microscopic examination 
10% KOH wet mount 
Both saliva and sputum samples were screened for yeast cells with 
or with out pseudohyphae. 
 
Gram’s Staining 
Uniform smears from saliva and the purulent, muco-purulent or 
blood stained portion of the sputum was prepared and subjected to 
Gram stain and examine for the presence of gram positive budding 
yeast cells with or with out pseudohyphae. 
 
Candida isolation 
The sputum and the saliva collected from the TB clinic attendees 
were subjected for the candida isolation by inoculating on to two 
sets of SDA , plates with antibiotics (Chloramphenicol 50mg/lit), one 
set incubated at 37°C, and the other set at 25-30°C(BOD) and 
observed for one week. The typical creamy, smooth, pasty colonies 
with yeasty odour were noted and recorded. The isolated Candida 
strains were furtherly identified as Candida species by the following 
methods ie, identifying pseudo mycelium, blastospore and 
chlamydospore formation on corn meal agar, germ tube production 
and also on growth on chrom agar (Hi-Media, Mumbai). 
 
Antifungal susceptibility test 
Antifungal susceptibility test was performed by disc diffusion method 
with commercially available antifungal discs- AmphotericinB 100 
units, Clotrimazole 10 mcg, Fluconazole 10 mcg, Ketoconazole 10 
mcg, Nystatin 100 units, Voriconazole 1 mcg, Itraconazole 30 mcg 
and  Miconazole 50 mcg all are supplied by Hi- Media 
pharmaceuticals, Mumbai.  Inoculum was prepared by picking five 
distinct colonies of Candida from fresh 24 hour old culture gown on 
SDA and incubated at 37º C. Colonies are suspended in 5ml sterile 
0.85% normal saline and adjusted to the turbidity to yield 106 cells 
per ml (ie 0.5 McFarland standards.) 
Anti mycotic sensitivity agar (Hi- Media) which had a depth of 4mm 
was prepared. A sterile non toxic cotton swab dipped in the standard 
inoculum and streaked the entire agar surface of the plate 3 times; 
turning the plate at 600 angle between each streaking. Then apply 
the discs using aseptic technique with a distance of at least 24mm, 
kept the plates at 370 c for 20-24 hrs. If it showed insufficient 
growth; read only after 48 hrs. The zone of inhibition around the 
discs were noted and recorded.     
 
Results 
A total of 3100 saliva and sputum samples were screened for 
Candida, among that, the direct microscopic examination of the 
sputum specimens revealed 44% and 91% yeast cells presence with 
10% KOH and Gram’s stain examination respectively whereas out of 
3100 saliva only 09% and 15% had shown yeast cells. Since the 
percentage of Candida isolates from the saliva (0.6%) was 
statistically insignificant, for better convenience, the sputum 
specimens alone processed for further test proceedings.  And 365 
(11.7%) of the sputum were found to be AFB smear positive. On 
sputum culture we obtained 638 (20.5%) Candida strains. The 
predominant species isolated was Candida albicans 561 strains 
(88%) followed by Candida tropicalis 38 (6%), Candida dubliniensis 
26 (4%) and Candida kruseii13 (2%). 
 
In detail totally 638 Candida strains isolated from the sputum of the 
TB clinic attendees from which 160 Candida strains belongs to AFB 
smear positive sputum and 478 Candida strains from AFB smear 
negative sputum 
 
Out of 365 smear positive AFB cases, 160 of their sputum yielded 
Candida growth. Candida albicans (n=131) was the predominant 
species among all other Candida species followed by Candida 
tropicalis (n=14), Candida dubliniensis (n=11) and Candida kruseii 
(n=4). 
 
The sputum (n=2735) of the patients with other respiratory tract 
infections yielded 478 (17.4%) Candida growth. On speciation the 
478 Candida strains were recorded as Candida albicans (n= 430), 
followed by Candida tropicalis (n= 24), Candida dubliniensis (n= 15) 
and Candida krusei (n= 9) (Table1).
  
Table1: Candida species isolated from the sputum of TB clinic attendees 
 
 
 
 
 
 
 
From our three years constant research we could able to record the 
antifungal resistance pattern of the Candida strains as follows, 25% 
antifungal resistance was expressed to Clotrimazole, Fluconazole 
and Ketoconazole 22% and 48% resistant to the antifungals 
Amphotericin B and Nystatin respectively. 
 
In detail out of 561 Candida albicans strains, (Table 2 & Figure 1) 
147 (26%) shown resistance to the antifungals Clotrimazole, 
Fluconazole, Ketoconazole and 24% and 51% resistance was 
recorded with the drugs Amphotericin B and Nystatin. 
Among 38 numbers of Candida tropicalis 13% resistance was 
recorded with Clotrimazole and Fluconazole while 16% resistance 
with Ketoconazole, 5% and 13% resistance with the antifungals 
Amphotericin B and Nystatin. 
 
About 26 Candida dubliniensis strains, 19% resistance was observed 
towards the drugs Clotrimazole, Fluconazole and Ketoconazole 8% 
and 35% with Amphotericin B and Nystatin. 
 
Out of 13 Candida krusei strains, 13% resistance was recorded with 
Nystatin and 8% resistance to rest of the antifungal drugs (Table2).
 
 
 
 
 
Candida Species 
Sputum Smear 3100 
AFB +ve 
365 
AFB-ve 
2735 
C. albicans 131 (35%) 430 (15.8%) 
C.  tropicalis  14 (3.8%) 24(0.9%) 
C. dubliniensis 11 (3%) 15(0.5%) 
C. kruseii 4 (1%) 9(0.3%) 
Total 160 (43.8%) 478 (17.4%) 
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Table 2: Antifungal drug resistance pattern of Candida strains 
 
 
 
Candida sp 
Sputum samples n= 
3100 
Antifungal Drug Resistance 
AFB + 
n=365 
AFB –ve 
n= 2735 
Azole % Ampho B % Nystatin % 
AFB sputum smear 
+ve -ve +ve -ve +ve -ve 
C.albicans 131 430 82 9 63 12 74 44 
C. tropicalis 14 24 21 8 14 8 35 37 
C. dubliniensis 11 15 20 20 0 13 40 33 
C. krusei 4 9 0 11 0 11 33 22 
 
Figure 1:  Antifungal drug resistance 
 
 
 
 
  
 
 
 
 
 
Among the 160 Candida strains isolated from the AFB smear positive 
sputum, 70% of them had shown resistance to the drugs 
Clotrimazole, Fluconazole and Ketoconazole, 53% and 66% 
resistance to the antifungals Amphotericin B and Nystatin. While out 
of 478 Candida strains isolated from the AFB smear negative sputum 
45 of them shown resistance to Clotrimazole and Fluconazole, 10% 
to Ketoconazole, 12% and 43% to the drugs Amphotericin B and 
Nystatin respectively. 
Out of 160 Candida strains isolated from the AFB smear positive 
sputum, 49(30%) strains found as multi drug resistant (MDR) strains 
while out of 478 Candida strains isolated from AFB smear negative 
sputum, 23 (4%) were recorded as MDR strains. The resistance 
pattern focused in Figure 3.  
The MDR Candida strains were tested with the newer antifungals 
(Table 3). All the species found to be sensitive to the drugs 
Itraconazole, Micanozole and Voriconazole except Candida albicans 
to which 49% resistance was recorded with Itraconazole and 
Voriconazole respectively, 44% resistance to Miconazole (Table 3). 
 
Table 3: 2nd Line Susceptibility Testing with Voriconazole, Miconazole and Itraconazole for MDR Candida 
 
Candida Species No: of strains Antifungal Drug Resistance 
AFB Smear 
+ve 
AFB Smear -
ve 
Vorico Mico Itraco 
AFB Smear 
+ve -ve +ve -
ve 
+ve -ve 
C.albicans 48 20 40 9 39 5 40 09 
C. tropicalis 01 02 0 0 0 0 0 0 
C. dubliniensis 00 01 0 0 0 0 0 0 
C. krusei 00 00 0 0 0 0 0 0 
 
 
Figure 2: Multi drug resistant candida strains isolated 
 
 
 
 
 
 
 
 
 
 
Figure 3: MDR Candida 
 
 
 
 
 
 
 
 
 
 
J Exp Sci Vol. 1, Issue 4, Pages 43-47 [2010] 
 
 
 
 
Figure 4: Multi drug Resistant Candida strain 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 a: Multi drug Resistant Candida Strain with newer antifungals also 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: A sensitive strain 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Different Candida species on Chrom Agar (Light green- Candida albicans, 
Blue- Candida tropicalis, Cream – Candida parapsilosis and Pink – Candida krusei.) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion  
In the 1990s, there was a significant increase in the prevalence of 
drug-resistant fungal infections due to Candida species in patients 
hospitalized for mucosal or systemic diseases.6-8 The widespread 
application of Fluconazole or related azole antifungals is postulated 
to promote selection of resistant subpopulations by shifting 
colonization to more naturally resistant species, such as Candida 
krusei or Candida glabrata.9-11 Alternatively, azole-resistant 
subspecies have arisen in vivo and in vitro that show changes in the 
target enzyme lanosterol 14-a-demethylase, in expression of multi 
drug efflux pumps, or in both.12-14The azoles, particularly 
Fluconazole, remain among the most common antifungal drugs, but 
their intensive clinical use for both therapy and prophylaxis has 
favored the emergence of resistant strains. 
There have been significant changes in the management of 
candidiasis in the last few years, particularly related to the 
appropriate use of echinocandins and expanded-spectrum azoles for 
candidemia, other forms of invasive candidiasis, and mucosal 
candidiasis. Pre disposing factors include malignant disease, 
diabetes mellitus, severe burns and cortico steroid therapy. The 
same background factors are found in the rare patient with Candida 
sinusitis or otitis media15.Aspiration of Candida in to the lung is 
uncommon, but can occur in the agonal stages of illness. Mouth 
flora and squamous cells are seen independent areas of the lung at 
autopsy, along with Candida.  
Infections due to Candida species necessitate the use of 
Fluconazole, Voriconazole, or the echinocandins because these 
isolates are frequently intrinsically resistant to AmphotericinB or 
develop resistance to AmphotericinB while the patient is on therapy 
and the antifungal therapy regimen needs constant vigil and 
requires periodical antifungal susceptibility/resistance evaluations.  
Resistance pattern of the Candida species to the azoles have been 
discussed by Jose et al 201015 and shown to have resistance to both 
azoles and Amphotericin B antifungals. So the alternative antifungal 
regimens are essential and the role of other combinations of 
antifungals to treat complicated Candida infections needs to be 
evaluated. Though recent research publications indicating the 
effective role of azoles and Amphotericin B and the newer antifungal 
drugs, 16, 17 still there seems to be occurrence of drug resistant 
Candida strains in the stream of certain infection. 
Candida species have various degrees of susceptibility to the 
frequently used antifungal drugs. The epidemiology of Candida 
infections has been extensively studied in North America and 
Europe18, where large surveillance programs exist. In Latin America, 
these data are limited17, with some regional studies in a few medical 
centers.18,19 Colombo et al17 carried out the largest multicenter study 
in eleven medical centers of nine Brazilian cities. 
To best of our knowledge there is no evidence based data available 
regarding the research studies related to the surveillance of drug 
resistance of Candida strains isolated from the sputum of TB clinic 
attendees especially from south India. In this situation we felt it is 
essential to carry out research study in this particular field.  
From our three years constant research, we could able to record the 
drug resistant Candida strains from the sputum of the pulmonary 
tuberculosis patients (93%) and 52% from tuberculosis negative 
patients with other respiratory tract infections respectively. 
Isolation of Candida dubliniensis for the first time in India was 
reported in 2003.20 Distribution of antifungal susceptibilities of 
Candida species from mucosal sites of HIV positive patients was 
studied by Parisa et al 2010 and resistance to Fluconazole and 
Itraconazole was more frequent antifungals shown to have 
resistance21. In our study we could also able to obtain Candida 
dubliniensis (26 out of 636 Candida strains) from the sputum of the 
TB clinic attendees from which it was recorded as, 11 and 15 from 
the sputum of pulmonary tuberculosis patients and non pulmonary 
tuberculosis patients with other respiratory tract infections 
respectively.  
From our study we conclude that the significant percentage (13%) 
of the resistant Candida strains have been isolated from the sputum 
of the TB clinic attendees with both the pulmonary TB cases and 
patients with other respiratory tract infections with out TB. Quite 
high level percentage (48%) of the resistance towards the 
antifungal drug Nystatin was observed from all the Candida species 
followed by Azole drug (24%) and Amphotericin B (22%). 
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The emergence of Candida antifungal resistance expressed as 
resistance to single drugs or to multiple drugs is the problem in 
treating the patients especially the patients those who are under 
immuno suppressive state and those who are already suffering from 
some other diseased condition. The failure in the treatment 
associated with Multi drug resistant which may increase the 
morbidity and mortality among such patients; therefore it requires 
prompt diagnosis and adequate antifungal therapy to these 
individuals.. Although studies demonstrate that antifungal resistance 
is relatively rare17,19,22, antifungal drugs have been used intensively 
either to control such infections or as prophylactic in long-term 
treatments, creating serious worries that might select for drug 
resistances, thus greatly harming infection control which was 
already mentioned by Pfaller et al and Yang et al.23,24  
Though controversial statement and views existing in this field, the 
positive look in to our view holds significance, since both 
tuberculosis negative and positive patients those who are all 
carrying these drug resistant Candida strains in their respiratory 
tract are comes under the first line in the spreading of these drug 
resistant Candida strains to others and to the society. For the public 
concern, a strong and steady prophylactic measure to be fixed to 
avoid the danger of spreading these resistant Candida strains. This 
could not be possible if any field of science or medical research fail 
to perform the initial step ie the screening of the drug resistant 
strains and their sources. 
From our constant study and the results obtained, we could 
conclude that the occurrence of drug resistant Candida strains in the 
sputum/ respiratory tract of the patients with respiratory tract 
infections is not uncommon and we suggest that the more extensive 
and elaborative studies in the field of screening the drug resistant 
Candida strain and its source to be performed, for the same, 
researchers should be directed in this field by the governing 
authorities and funding agencies.   
Therefore the periodical survey of the drug resistant Candida strains 
is essential not only to for the development of new antifungal drugs 
but also equally important in the appropriate antifungal drug 
selection for the earliest treatment for the patient care. By this we 
can suggest the related study in this field is essential either to 
support our study results or to criticize it.  
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